Department of Internal Medicine A, Meir Medical Center, Kfar Saba, Israel,
Department of Internal Medicine B, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel.
Acta Haematol. 2019;141(4):209-213. doi: 10.1159/000496555. Epub 2019 Apr 3.
A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical suspicion of opportunistic infections in patients receiving small-molecule kinase inhibitors. This report includes a review of reported cases of Aspergillus infections in patients receiving ibrutinib and the shared features of these cases.
一名 37 岁男性因套细胞淋巴瘤中枢神经系统复发而接受伊布替尼治疗时，出现中枢神经系统（CNS）曲霉菌病的非典型表现，入院治疗。该病例强调了在接受小分子激酶抑制剂治疗的患者中，对机会性感染保持高度临床警惕的重要性。本报告包括对接受伊布替尼治疗的患者中曲霉菌感染病例的回顾，以及这些病例的共同特征。
